USCWA
LGND icon

U.S. Capital Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28
Closed -$1.87K – 1127
2022
Q4 		$1.87K Buy
+28
New +$1.82K ﹤0.01% 1490

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

U.S. Capital Wealth Advisors's LGND Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2023, closing a stake of 28 shares — an estimated $1.87K sold.

U.S. Capital Wealth Advisors first reported a position in LGND in Q4 2022 and held it in 1 quarter. The position peaked at $1.87K in Q4 2022. 212 funds tracked by Wall St. Rank hold LGND as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 28 Ligand Pharmaceuticals shares in Q1 2023, an estimated $1.87K.
  • U.S. Capital Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Ligand Pharmaceuticals position peaked at $1.87K in Q4 2022.
  • 212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.